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SUMMARY
For many medical conditions several treatment options may be available for treating
patients. We consider evaluating markers based on a simple treatment selection pol-
icy that incorporates information on the patient’s marker value exceeding a threshold.
For example, colon cancer patients may be treated by surgery alone or surgery plus
chemotherapy. The c-myc gene expression level may be used as a biomarker for treat-
ment selection. Although traditional regression methods may assess the effect of the
marker and treatment on outcomes, it is appealing to quantify more directly the po-
tential impact on the population of using the marker to select treatment. A useful tool
is the selection impact (SI) curve proposed by Song and Pepe for binary outcomes [1].
However, the current SI method does not deal with continuous outcomes, nor does it
allow to adjust for other covariates that are important for treatment selection. In this
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paper, we extend the SI curve for general outcomes, with a specific focus on survival
time. We further propose the covariate specific SI curve to incorporate covariate
information in treatment selection. Nonparametric and semiparametric estimators
are developed accordingly. We show that the proposed estimators are consistent and
asymptotically normal. The performance is illustrated by simulation studies and
through an application to data from a cancer clinical trial.
KEYWORDS: biomarker; restricted survival time; selection impact curve; statistical
interaction.
1. INTRODUCTION
Selecting an appropriate treatment for patients is important when several treatment
options are available. Treatment selection may be facilitated by evaluating clinical
characteristics or biomarker measurements of patients at diagnosis. The rapidly ex-
panding biotechnologies, including gene expression arrays and imaging modalities,
show promises in providing useful biomarkers that may be used for selection of the
optimal treatment of disease [2]. For example, patients with colon cancer can be
treated by surgery alone or surgery plus chemotherapy. Surgery alone is less expen-
sive and has less side effects than surgery plus chemotherapy, but it may be less
effective as well, at least for some patients. It is desirable to identify the patients who
may benefit more from surgery based on biomarkers. A possible useful biomarker
is the c-myc gene, which is overexpressed in approximately 70% of human colonic
tumors [3]. Based on a study conducted by the Eastern Cooperative Oncoloty Group
(ECOG), Augenlicht et al. suggested that the c-myc gene may be of clinical prognos-
tic importance in patients with colon cancer [4]. Using a subset of the cases from this
2
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clinical trial, Li and Ryan indicated that there is an interaction between the c-myc
gene expression level and the two treatments on overall survival and disease progres-
sion free survival [5]. Using the same dataset, we estimated the overall survival and
the disease progression free survival by treatment and c-myc gene expression level.
Figure 1 shows the Kaplan-Meier estimates of the disease progression survival for
the four combinations of the two treatments and whether the c-myc gene expression
level exceeding 1.05, the 25% sample percentile. Although surgery plus chemother-
apy seems prolonging disease progression free survival better than surgery alone for
patients with c-myc level > 1.05, it is not that clear which treatment is better for
patients with c-myc level ≤ 1.05. The Kaplan-Meier estimates for the overall survival
show a similar pattern (not shown). This motivated us to assess using the c-myc gene
expression level for treatment selection for colon cancer patients.
In clinical protocols, treatment selection is often based on whether a marker value
exceeds a threshold. Some common examples include serum creatine > 1.3 mg/dL,
cholesterol > 200 mg/dL, and serum PSA > 4.0 ng/mL. As an analogy, we consider
selection of surgery alone versus chemotherapy plus surgery based on c-myc level
exceeding a threshold. To evaluate such policies, Song and Pepe proposed a graphical
tool, the selection impact (SI) curve, for selection between two treatments based on
binary response rate using a biomarker [1]. Let A = 0 denote one treatment and
A = 1 denote the other. The outcome T is dichotomous denoting success (T = 1) or
failure (T = 0) in curing a disease. Let Y be a continuous biomarker and larger values
of Y are potentially associated with better performance of treatment 1 versus 0 (Y
can be recoded if necessary to achieve this ). Consider the following treatment policy
that determines which treatment the patient receives based on a patient’s marker
3
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measure Y exceeding a threshold:
if Y > c , select treatment A = 1;
if Y ≤ c , select treatment A = 0, (1)
This implies that Y is known before treatment selection and generally a baseline
measurement. The population response (success) rate of the outcome corresponding
to this policy is
θ(v) = Pr{T = 1| treatment policy (1) }
where v = Pr[Y ≤ c] is the proportion of subjects with the marker value below c
and hence assigned to treatment 0. That is, θ is the proportion of subjects in the
population who respond if the treatment policy in effect is to assign a subject to
treatment 1 if his marker value exceeds c but to assign him to treatment 0 otherwise.
Observe that when c = −∞ or equivalently v = 0, the policy is that all patients
receive treatment 1 and none receive 0, while for c = ∞ or equivalently v = 1 all
patients receive treatment 0. As c increases from −∞ to∞, the proportion of subjects
assigned to treatment 0 increases from 0 to 1. There are two reasons for defining θ as
a function of quantile v. First, in evaluating a treatment policy of this sort, it will be
important to know the fractions of patients potentially assigned to treatment A = 0
versus A = 1 by the policy, 1 − v and v, respectively. Second, the display on this
scale allows one to compare policies based on different markers. In particular, even
if the markers are measured in different units, we can still compare the treatment
policies at a common percentile v, the larger θ(v) the better. The same idea has been
adopted for the receiver operative curve (ROC), which is widely used in evaluation of
4
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diagnostic tests [6, 7]. When the two treatments are comparable in all other aspects
including cost and side effects, then the optimal threshold maximizes the SI curve θ(v)
such that the overall success rate achieves the maximum. As illustrated in Figure 2,
based on the biomarker Y1, the best criteria would be to assign 40% patients to
treatment 0 whose biomarker value is less than the 40% percentile, while Y3 indicates
it would be best to assign all patients to treatment 1. Based on the biomarker Y2,
for any v between 0 and 0.4, the success rate would be the same if we assign patients
to treatment 0 whose biomarker value falls below the vth percentile. However, if
treatment 1 is more invasive, more expensive or has more side effects, we may want
to assign 40% patients to treatment 0 such that the overall success rate achieves the
maximum. Comparing the three biomarkers, it is obviously that policy based on Y1
achieves the best success rate.
The SI curve is essentially a curve of the population response rate versus the
percentile threshold. Compared to traditional regression models, this approach has
the advantage of quantifying more directly the potential impact on the population
of using the biomarker to select treatment. Specifically, we may choose an optimal
threshold based on the the SI curve. However, there is a need for further improvement
for wider applicability. First, the current SI curve methodology considers only binary
outcomes. It cannot be applied to continuous outcomes such as survival time, which
is frequently encountered in practice. For example, in the ECOG study, the outcome
of interest is the overall survival time and the disease progression free survival of the
colon cancer patients [5]. It may sometimes be desirable to select treatment based
on a utility measure that incorporates notions of cost and benefit when those factors
differ for the two treatments. Second, the current SI curve does not allow to adjust for
5
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other covariates, which may contain additional important information for treatment
selection. For colon cancer patients, the c-myc gene may be indicative for which
patients are likely to benefit more from surgery alone. The effect of c-myc gene may
be further impacted by covariates like gender and stage of cancer. For example, the
optimal threshold for c-myc gene expression level may be different for patients with
different covariate values. For example, Figures 3(a) and (b) show the Kaplan-Meier
estimates of disease progression free survival by treatment and c-myc gene expression
level above or below 1.05 for females and males separately. For either females or
males with c-myc level > 1.05, surgery plus chemotherapy seems better than surgery
alone in terms of prolonging disease progression free survival. However, for patients
with c-myc level ≤ 1.05, females seem benefited more from surgery plus chemothrapy
while it is not clear which treatment is better for males. In addition, the SI curve
methodology was not applied to any real dataset in [1]. It is of great interest to
demonstrate this method in real applications such as the ECOG study.
To overcome the limitations of the current SI curve methodology, we generalize
the current SI curve definition in two steps. First, we propose the SI curve for general
outcomes for evaluating markers on treatment selection; Second, we extend the SI
curve to adjust for covariates. In this paper, we focus specifically on survival time,
which is the outcome of interest in the ECOG data and is more challenging com-
pared to discrete and continuous outcomes without censoring. The same technique
can be easily adapted to the latter with only minor modifications. We propose the SI
curve based on the mean restricted survival time up to a given time L. The reason
of using mean restricted survival time is to avoid the infeasibility of estimating the
mean unrestricted survival time when censoring exists, that is, the mean unrestricted
6
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survival time may not be estimated if the largest observed survival time is censored
without some tail correction on the estimated survival function [8]. The technique
of restricting survival time has been used previously in estimating the mean lifetime
and quality-adjusted lifetime (see [9, 10] and the references therein). The restricted
survival time has also been widely used in practice, for example, in cancer statis-
tics, five year survival has been commonly used. Due to the existence of censoring,
the inference is more challenging than the binary case. A nonparametric estimator
is proposed to estimate the SI curve with no model assumptions on survival time.
To adjust for covariate effects, we further propose the covariate specific SI curve and
develop semiparametric estimators based on the proportional hazards model. Asymp-
totic properties of the estimators are derived using empirical process and U-process
theories. The approach can be adapted to uncensored continuous outcomes with some
modifications.
This paper is organized as follows. In Section 2, we define the SI curve for survival
time, develop the nonparametric estimator and derive its asymptotic properties. In
Section 3, we define the covariate specific SI curve. We further derive the semipara-
metric estimators and their asymptotic properties. The finite sample performance
of these estimators is assessed via simulation studies in Section 4 and illustrated by
application to the ECOG data in Section 5. The paper concludes with discussions in
Section 6.
7
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2. SELECTION IMPACT CURVE
2.1. Definition
We extend the SI curve to a general outcome W , that is, W can be either discrete
or continuous. We define the SI curve as
θ(v) = E {W |treatment policy (1)} .
Here v = Pr[Y ≤ c] is the proportion of patients assigned to treatment 0 under policy
(1). The SI curve considered in [1] is a special case of (2) when W is dichotomous.
In this paper, we focus on SI curve for survival time hereafter.
Using the notion of potential responses [11–13], for a = 0, 1, we define T a as the
survival time if a patient receives treatment A = a. It is impossible to observe T 0
and T 1 on the same patient; instead, we can only observe T = AT 1+ (1−A)T 0. Let
T ∗a = min(T a, L), be the corresponding restricted survival time by time L. Similarly,
T ∗0 and T ∗1 can not be observed on the same patient and only T ∗ = AT ∗1+(1−A)T ∗0
is observable. Both T and T ∗ are subject to censoring. We define the SI curve as the
mean restricted survival time corresponding to policy (1), that is,
θ(v) = E {T ∗ |treatment policy (1)} .
Noting that c is the v-th percentile yv of the biomarker Y and
E {T ∗ |treatment policy (1)} = P (Y > yv)E {T ∗ |treatment policy (1) andY > yv }
+P (Y ≤ yv)E {T ∗ |treatment policy (1) and Y ≤ yv } ,
under the common assumption that the potential responses (T ∗1, T ∗0) are independent
8
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from the treatment assignment A, it follows that
θ(v) = (1− v)E {T ∗1 |Y > yv}+ vE {T ∗0 |Y ≤ yv} (2)
(3)
When the two treatments are comparable, the optimal percentile vopt maximizes θ(v)
and the optimal threshold copt = F
−1(vopt). Otherwise, a utility measure incorporating
the survival time, cost and side effects can be used. We illustrate an application of a
simple utility measure in Section 5.
2.2. Estimation
We now consider estimation of θ(v) using data obtained from a randomized trial
where the failure time is subject to censoring. Let C denote the censoring time. The
observed survival data consist of X = min(T,C) and ∆ = I(T ≤ C). Suppose the
observations (Xi,∆i, Yi, Ai), i = 1, . . . , n, are an i.i.d. sample from the distribution of
(X,∆, Y, A). We make the following assumptions: (i) patients enrolled in the trial are
a simple random sample from the population of interest; (ii) the treatment assignment
for patients in the trial does not depend on his marker value, that is, Ai and Yi are
independent.
Noting that E {T ∗a |Y > yv } = E {T |Y > yv, T = a} (a = 0, 1), together with the
fact that for a non-negative random variable W , E(W ) =
∫∞
0
P (W ≥ w)dw [14, Ch
20, Sec 21], (2) can be rewritten as
θ(v) = (1− v)
∫ L
0
S(1)(t, yv)dt+ v
∫ L
0
S(0)(t, yv)dt,
where S(1)(t, y) = P (T ≥ t|A = 1, Y > y) and S(0)(t, y) = P (T ≥ t|A = 0, Y ≤
y). Therefore, an estimator of θ(v) can be obtained by substituting estimators for
9
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S(a)(t, y) (a = 0, 1) and yv. Here we use the Kaplan-Meier estimator of S
(a)(t, y),
Sˆ(a)(t, y) =
t
0
{
1− N
(a)
i (ds, y)
R
(a)
i (s, y)
}
,
where is the product integral notation, N
(1)
i (t, y) = I(Xi ≤ t,∆i = 1, Ai = 1, Yi >
y), N
(0)
i (t, y) = I(Xi ≤ t,∆i = 1, Ai = 0, Yi ≤ y), R(1)i (t, y) = I(Xi ≥ t, Ai = 1, Yi >
y), and R
(0)
i (t, y) = I(Xi ≥ t, Ai = 0, Yi ≤ y), N (a)i (ds, y) = N (a)i (s, y) − N (a)i (s−, y).
To estimate yv, we use the nonparametric estimator yˆv = Fˆ
−1
Y (v), where FˆY (y) =
n−1
∑n
i=1 I(Yi ≤ y) is the empirical distribution of Y . Thus an estimator of θ(v) can
be written as
θˆ(v) = (1− v)
∫ L
0
Sˆ(1)(t, yˆv)dt+ v
∫ L
0
Sˆ(0)(t, yˆv)dt.
This is a nonparametric estimator. It does not require any parametric assumptions
on the survival time and the biomarker. Moreover, it is invariant to any monotone
increasing transformation of the biomarker.
Now we derive the asymptotic properties of θˆ(v) using empirical process theory.
The idea is to first show that n1/2
{
Sˆ(a)(t, y)− S(a)(t, y)
}
converges to a Gaussian
process under some regularity conditions. Since θˆ(v) is a composite function of Sˆ(0),
Sˆ(1) and FˆY , the asymptotic distribution of θˆ(v) is then derived by the functional delta
method [15, Ch 3.9]. Specifically, we can show that n1/2
{
θˆ(v)− θ(v)
}
converges to a
Gaussian process. The details of the asymptotic distribution and the proof are given
in [16].
The covariance formula for θˆ(v) contains the density function of Y and the deriva-
tive of the cumulative hazard functions of T conditional on (A = 1, Y > y) or
(A = 0, Y ≤ y). Usually smoothing techniques are needed to estimate these quan-
tities. In applications, to avoid the complexity of the smoothing approaches, for
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simplicity, we use the bootstrap method to calculate the standard error and confi-
dence band for θ(v). This is justified by the empirical process theory for the bootstrap
given in [15, Ch 3.9]. Let Θ = {(Xi,∆i, Yi, Ai) : i = 1, . . . , n} be the observed data
set, and ΘB be the B
th resampling bootstrap dataset, where B = 1, . . . ,M . Let
θˆB(v) be the estimator based on ΘB. Then supv∈[p,q] |θˆB(v)− θˆ(v)| given Θ is asymp-
totically equivalent to supv∈[p,q] |θˆ(v) − θ(v)|, 0 < p < q < 1. Let cα be the 1 − α
quantile of supv∈[p,q] |θˆB(v) − θˆ(v)|, then a level 1 − α confidence band for θ(v) is
(θˆB(v)− cα, θˆB(v)+ cα). The standard error of θˆ(v) can be estimated by the standard
deviation of {θˆB(v) : B = 1, . . . ,M}.
The optimal percentile vopt can be estimated by vˆopt, which maximizes θˆ(v).When
vopt is an interior point in the interval [0, 1], under some regularity conditions, it can
be shown that vˆopt is asymptically normal. The standard errors of vˆopt can be obtained
via bootstrap. The Optimal threshold coptcan be estimated by cˆopt = Fˆ
−1
Y (vˆopt).
3. COVARIATE SPECIFIC SELECTION IMPACT CURVE
So far, we have considered treatment selection based only on the biomarker. There are
situations that covariates other than the biomarker may impact treatment selection.
Thus it is important to adjust for such covariates. For example, if we use c-myc gene
expression level to select patients for surgery alone or surgery plus chemotherapy, we
may want to adjust for sex. If the covariates are discrete, it is possible to consider a
separate SI curve for each covariate combination. However, this will not work when
there exist continuous covariates. In addition, even if all covariates are discrete, the
sample size for some covariate combination may be too small to obtain a reliable SI
curve estimate. It is noticeable that the SI curve bears some similarities to the ROC
11
Hosted by The Berkeley Electronic Press
curve used to evaluate diagnostic tests based on a biomarker [17]. To account for
covariate effects, the ROC curve has been extended to the covariate specific ROC
curve [6, 7]. This motivates us to propose the covariate specific SI curve by analogy
to the covariate specific ROC curve.
3.1. Definition
Let Z denote the vector of K covariates that may impact the treatment selection
other than the biomarker. To incorporate the covariates, we consider the following
treatment policy given Z = z:
if Y > yv,z , select treatment A = 1;
if Y ≤ yv,z , select treatment A = 0. (4)
Here yv,z is the vth quantile of the conditional distribution of Y given Z = z. The
corresponding covariate specific SI curve is defined as
θ(v|z) = E {T ∗ |treatment policy (4)}
Using similar arguments as those for the unadjusted SI curve θ(v), we can show that
θ(v|z) = (1− v)E {T ∗1 |Y > yv,z,Z = z}+ vE {T ∗0 |Y ≤ yv,z,Z = z} . (5)
This definition is general to any outcomes, include binary and continuous outcomes.
It reduces to the unadjusted SI curve given in (2) when there is no covariate.
The covariate specific SI curve considers treatment selection conditional on the
covariate Z, which may be different for various values of Z. For a given value of
z, the optimal threshold vˆopt(z) can be obtained by maximizing θ(v|z). It provides
a useful tool for policy makers to choose different biomarker thresholds based on the
values of Z.
12
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3.2. Estimation
Now we consider estimation of θ(v|z) using data obtained from randomized trials,
which satisfies condition (i) and (ii) described in Section 2.2 and (iii)′ A is independent
of Y given Z. Suppose we have independent and identically distributed observations
(Xi,∆i, Yi, Ai,Zi), i = 1, . . . , n.
With some simple algebra, it can be shown that (5) can be rewritten as
θ(v|z) =
∫ 1
v
∫ L
0
S(t|u, z, 1)dtdu+
∫ v
0
∫ L
0
S(t|u, z, 0)dtdu, (6)
where S(t|u, z, a) = P{T ≥ t|Y = yu,z,Z = z, A = a}. An estimator of θ(v|z) can
be obtained based on (6).
Assume that the hazard of failure follows the proportional hazards model
λi(t|Vi,Zi, Ai) = λ0(t) exp
[
βT0 g {Vi,Zi, Ai}
]
, (7)
where Vi = FY |Z(Yi|Zi), FY |Z(·|z) is the conditional distribution function of Y given
Z = z, and g(v, z, a) is a known r-dimensional function. It is useful to write the
model in terms of Vi, since θ(v) is considered a function of v for the reasons mentioned
earlier. For example we might use the model
λi(t|Vi,Zi, Ai) = λ0(t) exp
[
β1D(Vi,Zi) + β
T
2 Zi + β3Ai + β4D(Vi,Zi)Ai
+βT5 D(Vi,Zi)Zi + β6ZiAi + β
T
7 D(Vi,Zi)ZiAi
]
,
where D(v, z) is a function of v and z. When D(v, z) = F−1Y |Z(v|z), D(vi,Zi) is just
the biomarker Yi. Further assuming that FY |Z(·|z) is known, based on (6), we can
estimate θ(v|z) by
θ˜(v|z) =
∫ 1
v
∫ L
0
Sˆ(t|u, z, 1)dtdu+
∫ v
0
∫ L
0
Sˆ(t|u, z, 0)dtdu,
13
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where
Sˆ(t|v, z, a) = exp
{
−Λˆ0(t) exp
(
βˆTg(v, z, a)
)}
is an estimator for the survival function S(t|v, z, a), βˆ is the partial likelihood esti-
mator of β0, and Λˆ0(t) is the Breslow estimator of the baseline cumulative hazard
function Λ0(t).
In practice FY |Z is usually unknown. We assume the conditional distribution of
Y given Z following the semiparametric model [18, 19],
FY |Z(y|z) = h(y − γT0 z), (8)
where h(·) is an unknown distribution function. The estimator γˆ of γ0 can be obtained
by solving
n∑
i=1
(Yi − γTZi)Zi = 0.
The function h(y) can be estimated by
hˆ(y; γˆ) = n−1
n∑
i=1
I(Yi − γˆTZi ≤ y).
Let β˜ be the solution to the partial likelihood estimating equation with FY |Z(y|z)
replaced by hˆ(y− γˆTz; γˆ) and Λ˜0(t) be the corresponding Breslow estimator of Λ0(t).
An estimator of θ(v|z) is
θ˜∗(v|Z) =
∫ L
0
∫ 1
v
S˜(t|v, z, 1)dudt+
∫ L
0
∫ v
0
S˜(t|v, z, 0)dudt,
where
S˜(t|v, z, a) = exp
{
−Λ˜0(t) exp
(
β˜Tg(v, z, a)
)}
.
Note that both θ˜ and θ˜∗ can also be used in the case of no covariates. Since these esti-
mators are semiparametric estimators, they are more efficient than the nonparametric
14
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estimator θˆ under the correct model assumptions. However, if the model assumptions
are violated, inference based on these estimators can be misleading. We may need
to transform the biomarker appropriately to assure that the proportional hazards
assumption holds. In contrast, the nonparametric approach is invariant to monotone
increasing transformations.
Under some regularity conditions, we can show that both n1/2
{
θ˜(v|z)− θ(v|z)
}
and n1/2
{
θ˜∗(v|z)− θ(v|z)
}
converge to zero-mean Gaussian processes. The deriva-
tion is involved with application of empirical process and U-process theories. The
details of the asymptotic distribution and the proof are given in [16]. A consistent
estimator for the variance of θ˜(v|z) is given in equation (B.4), which involves complex
integrals. The variance formula for θ˜∗(v) is even more complicated and involves the
derivative of the unknown function h(·). In practice, by analogy to the nonparametric
case, we can use the bootstrap method to compute estimates of the standard errors
and confidence bands for θ˜(v|z) and θ˜∗(v|z).
The optimal percentile vopt(z) can be estimated by v˜opt(z) and v˜
∗
opt(z), which
maximizes θ˜(v|z) and θ˜∗(v|z) respectively. When vopt(z) is an interior point in the
interval [0, 1], under some regularity conditions, it can be shown that v˜opt(z) and
v˜∗opt(z) are asymptotically normal. The variance of v˜opt(z) and and v˜
∗
opt(z) can be
obtained via bootstrap. The optimal threshold vopt(z) can be estimated by c˜opt(z) =
FY |Z(v˜opt(z)|z) and c˜∗opt(z) = FˆY |Z(v˜∗opt(z)|z) correspondingly.
Note: We have derived the asymptotic properties of estimators of the overall SI
curve and the covariate adjusted SI curve in an interval excludes v = 0 and v = 1.
However, the asymptotic normality still holds at v = 0 and v = 1 by noticing that the
nonparametric estimator essentially does not include the term yv at v = 0 and 1 and
15
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the proof can be easily modified for the asymptotic normality of the semiparametric
estimators.
4. SIMULATION STUDIES
Simulation studies were conducted to assess the finite sample properties of the esti-
mators. We assess the performance of the estimators at boundary points v = 0 and
v = 1 as well as internal v points.
Case I : We first considered the simple case of no covariates when both the non-
parametric and semiparametric estimators can be used. We generated data for 100
and 300 patients in a randomized trial with P[A = 1] = 0.5. The marker Y was
generated from the standard normal distribution. The survival time was gener-
ated according to the proportional hazards model (7) with g(v, z, a) = (v, a, va)T ,
β = (1, 0.5,−2.6)T , and λ0(t) = 0.1. Censoring time was generated from an expo-
nential distribution with mean 30 and truncated at 20, leading to a censoring rate of
about 30%. Consider L = 15, and the SI curve is shown in Fig. 4.
We estimated the SI curve using θˆ, θ˜ and θ˜∗ for 500 simulated data sets. The
estimated standard errors were computed by the bootstrap method using 100 resam-
pled data sets for all the estimators. For each estimator, the 95% Wald confidence
intervals were calculated. Table 1 presents the results for v = 0.0, 0.1, . . . , 1.0. All
the estimators exhibit negligible bias, and the standard errors track the true standard
deviations of the estimators well. The coverage probabilities are close to their nomi-
nal levels. As expected, θ˜∗ is less efficient than θ˜ because the true FY is used for the
former while FY is estimated for the latter, but the efficiency loss is small. Moreover,
θ˜∗ is more efficient than the nonparametric estimator θˆ as expected.
16
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Case II : To investigate the robustness of the estimators, we also conducted simu-
lations under similar scenarios as above except that the survival time was generated
from a gamma distribution with the shape parameter equal to 4 and the scale param-
eter equal to {5λi(t, Yi,Zi)}−1, where λi(t, Yi,Zi) has the same form of the hazard
in Case I with β = (−4,−2, 1)T and λ0(t) = 2. In this case, the survival model is
misspecified for the semiparametric estimators. The results are shown in Table 2.
The nonparametric estimator θˆ still works well while the semiparametric estimators
are obviously biased with poor coverage probabilities for the confidence intervals.
Case III: We then considered the case when a covariate Z was included. The
covariate Z was generated from a standard normal distribution. The biomarker Y
equals Z plus a standard normal error. The survival time followed the proportional
hazards model (7) with g(v, z, a) = (v, a, z, va, vz, az, vaz)T , β = (1,−0.7,−0.1,−0.9,
−0.3, 0.8,−0.9), and λ0(t) = 0.2. Censoring time was generated from an exponential
distribution with mean 20 and truncated at 8, leading to a censoring rate of about
30%. Consider L = 5 and the covariate SI curves for z = −1, 0, 1 are shown in Fig. 5.
We estimated the covariate specific SI curves for 500 simulated datasets with n = 100
and 200 using θ˜ and θ˜∗. The results in Table 3 show similar patterns as above and
both estimators work well.
We all assessed the estimation of the optimal percentile under case I, where the
optimal percentile vopt = 0.196. The results are shown in table IV. The confidence
interval are computed via bootstrap, which works better than the asymptotic confi-
dence interval at these sample sizes in our numerical study. Overall the estimators
work reasonably well. The nonparametric estimator is less efficient than the semi-
parametric estimators.
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In summary, the nonparametric estimator θˆ is robust while the semiparametric
estimators θ˜∗ and θˆ depend on the correct specification of the models. Obvious
deviances between these estimators may indicate violation of the model assumptions
for the semiparametric estimators. We recommend using the nonparametric estimator
when there is no covariates. Extension of the semiparametric estimators to more
flexible models is discussed in Section 6.
5. APPLICATION
As an illustration, we applied the proposed approaches to a subset of the ECOG clin-
ical trial, which was analyzed in [5]. In this subset, disease progression free survival
and c-myc expression level was measured on 92 patients randomized to receive surgery
alone or surgery plus chemotherapy, among which 47 were males and 45 were females.
The analysis in [5] focused on assessing whether there was a c-myc effect and/or a
treatment/c-myc interaction. This is different from our goal here, which is to assess
whether the c-myc expression level can be used to select patients for surgery alone
versus surgery plus chemotherapy. We estimated the SI curve using both the nonpara-
metric and semiparametric methods. For the semiparametric approach, we included
log c-myc expression level Y , treatment indicator A = I(surgery plus chemotherapy)
and their interaction in the the proportional hazards model. This model was also
used in [5]. This corresponds to g(v, z, a) = (v, a, va)T in the proportional hazards
model (7). We consider the mean disease progression free survival time restricted
to five years. Since the distribution FY (y) is unknown, we estimated the SI curve
using the estimators θˆ(v) and θ˜∗(v). The estimates and the 95% pointwise confidence
intervals and simultaneous confidence bands are shown in the left panel of Figure 6.
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The semiparametric estimate is essentially a smoothed version of the nonparametric
estimate, which indicates that the corresponding model assumptions are appropriate
for this dataset. The estimated SI curves seem to decrease with v with the estimated
optimal percentile 0.00 (se= 0.153). That is, assigning all patients to surgery plus
chemotherapy may achieve the maximum mean survival time within 5 years. How-
ever, this may not be the optimal treatment policy considering that surgery plus
chemotherapy has more side effects than surgery alone and the estimated SI curve is
almost horizonal for v in (0, 0.3).
To take into account of the side effect of chemotherapy, we may consider a utility
measure U , for example, U = T ∗ − dA, where d is a nonnegative weight denoting
the deteriorating effect of chemotherapy on the survival time; that is, a person may
prefer surgery alone if the additional chemotherapy does not lengthen the survival
time by at least d. The SI curve based on U can be obtained by shifting the SI curve
based on T ∗ by w(1− v) and hence can be easily estimated. The optimal percentile
can be achieved by maximizing the SI curve based on U . The right panel of Figure 6
shows the corresponding nonparametric and semiparametric estimates with d = 0.5.
The estimated optimal percentile is 0.322 (se= 0.245) and corresponding estimated
threshold is 0.118 based on the semiparametric SI curve estimate. This indicates that,
considering the c-myc expression level and the side effect of chemotherapy, the optimal
treatment policy may be the one that assigns patients whose log c-myc expression
level falls below 0.118 (32.2% percentile) to surgery alone. The maximum point of
the nonparametric estimate may be less stable since the non-smoothness of the curve.
We do not see significant difference on either estimate across v which may due to the
small sample size of this dataset. Whether the difference is clinically important may
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be worth future investigation with larger clinical trials.
As we have discussed in Section 1, it is also of interest to assess whether the
gender of the patient may affect the treatment selection. Although we may estimate
a separate SI curve for males and females, the estimate may be unreliable because of
the small sample size in each group. We thus estimated the covariate specific SI curve
based on T adjusting for Z = I(gender=male) using the semiparametric estimator
θ˜∗(v|z) by further including Z and all the two-way and three-way interactions in the
proportional hazards model considered above. The left panel of Figure 7 shows the
results. For male patients, the SI curve seems to be horizontal when v is small and
decline thereafter, while for female patients the SI curve tends to decrease for v from
0 to 1. This indicates the optimal thresholds treatment selection should be different
for males and females. The estimated optimal percentiles are 0.00 (se= 0.265) are
females and 0.130 (se= 0.207) with the corresponding estimated threshold −0.033 for
males. To take into account of the side effect of chemotherapy, the covariate specific
SI curves based on U were also estimated as shown in the right panel of Figure 7. The
estimated optimal percentiles are 0.00 (se= 0.345) for females and 0.239 (se= 0.252)
with the corresponding estimated threshold 0.077 for males. Thus we may want to
assign almost all females to surgery plus chemotherapy while assign male patients
whose log c-myc expression level fall below 0.077 (23.3% percentile) to surgery alone.
To ensure the validity of these estimators, we checked the proportional hazards
assumptions for the models using the method in [20, Ch 6.2]. There were no evidences
against the proportional hazards assumptions.
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6. DISCUSSION
We have proposed the SI curve for the survival time to evaluate the impact of a
treatment selection policy based on Y > yv. Both nonparametric and semiparametric
estimators are derived. We recommend using the nonparametric estimator when it is
not necessary to adjust for covariates because of its robustness. The semiparametric
estimators are less robust, but can be more efficient under the correctly specified
model. In addition, they can easily incorporate covariates in estimation. Whether
to use the unadjusted or adjusted SI curve depends on the specific treatment policy,
that is, whether we would like to select the treatment based on the biomarker alone.
For the semiparametric approach, we have used the standard proportional hazards
model to characterize the relationship between the survival time and the marker and
the covariates. This can be easily adapted to more flexible models. For example, we
can use other survival models, such as the stratified proportional hazards model, the
accelerated failure time model and the transformation model, as long as we can obtain
consistent estimators for the survival distribution. The nonparametric transformation
model [21] may be an attractive extension as it includes most popular survival models
as special cases, such as the proportional hazards model and the accelerated failure
time model. The semiparametric location model (8) is used only for estimating the
conditional distribution function FY |Z . We can remove this assumption and estimate
FY |Z by kernel smoothing method when the number of covariates is small and the
sample size is relatively large, since the kernel smoothing method may not work well
otherwise.
Although the SI curve is proposed based on the restricted mean survival time, it
can be extended to other statistical measures. For example, a utility function that
21
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incorporates notions of cost and quality of life might be employed. Although we have
focused on survival time as outcomes, the approach can be adapted to discrete and
continuous outcomes with minor modifications.
In this paper, we consider SI curves based on a single biomarker. In practice,
there may exist multiple biomarkers. For example, multiple genes may be related to
a specific disease or affect the survival time. An important issue is how to combine
these biomarkers for treatment selection. On the other hand, it may be needed to
select among more than two treatments. These issues will be investigated in our
future research.
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Table IV. Estimation of the optimal percentile under case I.
n = 100 n = 300
vopt est SD SE CP est SD SE CP
vˆopt 0.192 0.271 0.133 0.133 0.938 0.239 0.095 0.097 0.954
v˜opt 0.192 0.187 0.118 0.105 0.916 0.190 0.077 0.071 0.926
v˜∗opt 0.192 0.189 0.120 0.108 0.928 0.190 0.079 0.073 0.928
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Figure 1. Kaplan-Meier estimates of disease progression free survival by treatment
and c-myc level
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Figure 2. Example of SI curves
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Figure 3. Kaplan-Meier estimates of disease progression free survival by treatment
and c-myc level for different genders.
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Figure 4. True SI curve in simulation. Solid line, proportional hazards model; dashed
line, Gamma survival distribution.
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Figure 5. True covariate specific SI curve in simulation.
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Figure 6. Estimated SI curve for ECOG data. Left panel is based on 5 year restricted
survival time T ∗, right panel is based on the utility function U = T ∗ − 0.5A. Non-
parametric estimate θˆ, dotted curve; semiparametric estimate θ˜, solid curve. 95%
confidence bands are shown with the outer curves, 95% pointwise confidence intervals
are shown with the intermediate curves, the estimates themselves are shown with the
center curves.
32
http://biostats.bepress.com/uwbiostat/paper375
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
v
q^
(v
)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
v
q^
(v
)
(a) Female
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
v
q^
(v
)
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
v
q^
(v
)
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Figure 7. Estimated SI curves adjusted for gender for ECOG data. Left panel is
based on 5 year restricted survival time T ∗, right panel is based on the utility function
U = T ∗−0.5A. 95% confidence bands are shown with the outer curves, 95% pointwise
confidence intervals are shown with the intermediate curves, the estimates themselves
are shown with the center curves.
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